These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 15776365)

  • 1. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model.
    Lipatov AS; Webby RJ; Govorkova EA; Krauss S; Webster RG
    J Infect Dis; 2005 Apr; 191(8):1216-20. PubMed ID: 15776365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of and immunity to avian influenza A H5 viruses.
    Katz JM; Lu X; Frace AM; Morken T; Zaki SR; Tumpey TM
    Biomed Pharmacother; 2000 May; 54(4):178-87. PubMed ID: 10872716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.
    Lu X; Edwards LE; Desheva JA; Nguyen DC; Rekstin A; Stephenson I; Szretter K; Cox NJ; Rudenko LG; Klimov A; Katz JM
    Vaccine; 2006 Nov; 24(44-46):6588-93. PubMed ID: 17030078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.
    Govorkova EA; Webby RJ; Humberd J; Seiler JP; Webster RG
    J Infect Dis; 2006 Jul; 194(2):159-67. PubMed ID: 16779721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain.
    Droebner K; Haasbach E; Fuchs C; Weinzierl AO; Stevanovic S; Büttner M; Planz O
    Vaccine; 2008 Dec; 26(52):6965-74. PubMed ID: 18848593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets.
    Song MS; Oh TK; Pascua PN; Moon HJ; Lee JH; Baek YH; Woo KJ; Yoon Y; Sung MH; Poo H; Kim CJ; Choi YK
    Vaccine; 2009 May; 27(24):3145-52. PubMed ID: 19446184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-protection of mice immunized with different influenza A (H2) strains and challenged with viruses of the same HA subtype.
    Govorkova EA; Smirnov YuA
    Acta Virol; 1997 Oct; 41(5):251-7. PubMed ID: 9607078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.
    Stephenson I; Bugarini R; Nicholson KG; Podda A; Wood JM; Zambon MC; Katz JM
    J Infect Dis; 2005 Apr; 191(8):1210-5. PubMed ID: 15776364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice.
    Cox RJ; Hovden AO; Brokstad KA; Szyszko E; Madhun AS; Haaheim LR
    Vaccine; 2006 Nov; 24(44-46):6585-7. PubMed ID: 16839650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.
    Lalor PA; Webby RJ; Morrow J; Rusalov D; Kaslow DC; Rolland A; Smith LR
    J Infect Dis; 2008 Jun; 197(12):1643-52. PubMed ID: 18513153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice.
    Hovden AO; Cox RJ; Madhun A; Haaheim LR
    Scand J Immunol; 2005 Oct; 62(4):342-52. PubMed ID: 16253121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
    D'Aoust MA; Lavoie PO; Couture MM; Trépanier S; Guay JM; Dargis M; Mongrand S; Landry N; Ward BJ; Vézina LP
    Plant Biotechnol J; 2008 Dec; 6(9):930-40. PubMed ID: 19076615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.